able health authority product registrations. S H-218301-AA JAN 2014 Page 10 of 32 Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for the use only in countries with applicable health authority product registrations. S H-218301-AA JAN 2014 20% 的卒中发生于房颤患者 1房颤患者卒中风险较非房颤患者高 5 倍 2房颤所致脑卒中具有高致残率、高病死率及高复发率的特点 3 卒中是中国居民第一大死因,同时也是致残的首要原因。 AF AF: Atrial Fibrillation ⑴ Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med. 1999. ⑵ Holmes DR, Atrial Fibrillation and Stroke Management: Present and Future, Seminars in Neurology 2010;30:528 – 536 ⑶ Yang G, et al. Rapid health transition in China, 1990-2010. Lancet 2013;381(9882):1987 – 2015.
全文预览